Rojo F, Lazaro C, Abdulkader-Nallib I, et al. Homologous recombination deficiency tumor tissue testing in a real-world cohort of tubo-ovarian carcinoma patients: validation of decentralized genomic profiling in 4777 cases. Virchows Archiv. 2026. https://doi.org/10.1007/s00428-026-04476-4 — Virchows Archiv
Iglesias Docampo L, Basté N, Oliver M, et al. Randomized non-comparative phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma unable for cisplatin-based chemotherapy. NIVOTAX TTCC study. Eur J Cancer. 2026;241:116775. https://doi.org/10.1016/j.ejca.2026.116775 — Eur J Cancer
Álvarez-Gallego R, et al. Phase II study of NALIRIFOX plus liquid biopsy KRAS assessment in advanced pancreatic cancer. Am J Clin Oncol. 2025. DOI:10.1097/COC.0000000000001253 — Am J Clin Oncol
Varela M, Teixidó C, Álvarez-Fernández C, et al. Prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer in Spain: the ORIGEN study. Transl Lung Cancer Res. 2025;14(4):1254-1265. https://dx.doi.org/10.21037/tlcr-2024-1146 — Transl Lung Cancer Res
Mangues-Bafalluy I, Bernárdez B, Martínez-Sesmero JM, et al. Adherence to oral antineoplastic therapy among patients with advanced or metastatic non-small cell lung cancer: a noninterventional, prospective study. J Cancer Res Clin Oncol. 2025;151:224. https://doi.org/10.1007/s00432-025-06264-0 — J Cancer Res Clin Oncol
Areses Manrique MC, León-Mateos L, Silva-Díaz S, et al. Real-world clinical experience with osimertinib in advanced EGFR-mutated non-small cell lung cancer. Clin Transl Oncol. 2025. https://doi.org/10.1007/s12094-025-04015-8 — Clin Transl Oncol
Sosa-Fajardo P, Martín-Martín M, Luna-Tirado J, et al. Stage III NSCLC Treatment Patterns in Spain: A Population-Based Study of the GOECP-SEOR. Cancers. 2025;17:3807. https://doi.org/10.3390/cancers17233807 — Cancers
Rodríguez Abreu D, Lázaro M, López-Brea M, et al. OSIREAL (201eP): Safety of first-line osimertinib in patients with EGFRm locally advanced or metastatic non-small cell lung cancer. Poster. European Society for Medical Oncology (ESMO) Congress 2025. — Ann Oncol (Suppl)
Artal Á, Cardeña A, Lázaro M, et al. OSIREAL (274eP): Osimertinib as adjuvant treatment in EGFRm non-small cell lung cancer — real-world evidence from OSIREAL study. Poster. European Society for Medical Oncology (ESMO) Congress 2025. — Ann Oncol (Suppl)
Rodríguez Abreu D, et al. OSIREAL (30P): First-line osimertinib for patients with EGFRm locally advanced/metastatic non-small cell lung cancer — effectiveness analysis. Poster. European Society for Medical Oncology (ESMO) Congress 2025. — Ann Oncol (Suppl)
Manso L, Sánchez-Bayona R, Guerra JA, et al. PALBOBIN: A phase IB study of binimetinib and palbociclib in molecularly selected advanced triple-negative breast cancer. Cancer Res. 2025. https://doi.org/10.1158/2767-9764.CRC-25-0428 — Cancer Res
Lindemann K, et al. BEATcc (ESMO Gynaecological Cancers): Efficacy according to PD-L1 status in the BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) randomised phase 3 trial of first-line atezolizumab, chemotherapy and bevacizumab for metastatic, persistent or recurrent cervical cancer. Poster. ESMO Gynaecological Cancers Annual Congress 2025. — Ann Oncol (Suppl)
Méndez-Vidal MJ, et al. PARASEC: Safety and efficacy of radium-223 combined with enzalutamide or abiraterone in mCRPC patients with bone metastases. Poster. American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium 2025. — J Clin Oncol (Suppl)
Méndez-Vidal MJ, et al. PARASEC: Safety and efficacy of radium-223 combined with enzalutamide or abiraterone in metastatic castration-resistant prostate cancer patients with bone metastases. Clin Transl Oncol. 2025. https://doi.org/10.1007/s12094-026-04233-8 — Clin Transl Oncol
Galán-Gómez A, et al. PRISMA-1: Pembrolizumab as maintenance therapy in patients with advanced urothelial carcinoma. Poster. American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium 2025. — J Clin Oncol (Suppl)
Méndez-Vidal MJ, et al. BLARWE (Abstract 702): Bladder cancer real-world evidence study. Poster. American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium 2025. — J Clin Oncol (Suppl)
Gironés R, et al. EVITA: Enfortumab vedotin in previously treated advanced urothelial carcinoma patients. The Oncologist. 2025. — The Oncologist
Sibai H, et al. DUTRENEO: Durvalumab plus tremelimumab for muscle-invasive bladder cancer — translational analysis. Cell Reports. 2025;44:115229. — Cell Reports
Climent MA, Sanchez-Escribano R, Heras L, et al. Pilot phase 2 study of the efficacy, safety, and tolerability of first-line cabozantinib for older fragile patients with metastatic renal cell carcinoma: The SOGUG-CABOMAYOR study. J Geriatr Oncol. 2025;16(8):102340. https://doi.org/10.1016/j.jgo.2025.102340 — J Geriatr Oncol
Muñoz C, et al. Watch-and-wait strategy in locally advanced rectal cancer after total neoadjuvant therapy with NALIRIFOX. Am J Clin Oncol. 2024. DOI:10.1097/COC.0000000000001157 — Am J Clin Oncol
Mangues-Bafalluy I, Bernárdez B, Martínez-Sesmero JM, Navarro-Ruiz A, Rubio-Salvador AR, Martín-Conde MT. Treatment adherence to oral chemotherapy in patients with locally advanced or metastatic non-small cell lung cancer: Protocol for a hospital pharmacy-based real-world study. Farm Hosp. julio de 2024;S1130634324000989 — Farm Hosp
Mangues-Bafalluy I, Bernardez B, Martínez Sesmero JM, et al. LOADH (Poster 393): Healthcare resource utilization according to adherence to oral antineoplastics — LOADH study. Poster. 69th National Congress SEFH 2024. — Farm Hosp (Suppl)
Segura P, et al. Healthcare resource utilization and associated costs among patients with advanced non-small-cell lung cancer receiving chemotherapy or immunotherapy in Spain: a single-center, real-world, exploratory study. Cancers. 2024;16:2068. https://doi.org/10.3390/cancers16112068 — Cancers
Iglesias Docampo L, Basté N, Oliver M, et al. NIVOTAX TTCC-2019-01 (871P): Randomized phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic HNSCC unable for cisplatin-based chemotherapy. Poster. European Society for Medical Oncology (ESMO) Congress 2024. — Ann Oncol (Suppl)
Salazar Saez R, Zorrilla M, Sánchez R, et al. Molecular analysis of BRCA1 and BRCA2 genes in La Rioja (Spain): five new variants. Hereditary Cancer Clin Pract. 2024;22:22. https://doi.org/10.1186/s13053-024-00296-2 — Hereditary Cancer Clin Pract
Gutiérrez-Pérez C, et al. Single-center real-world study of atezolizumab for urothelial carcinoma. Clin Transl Oncol. 2024. — Clin Transl Oncol
Oaknin A, Gladieff L, Martínez-García J, Villacampa G, Takekuma M, De Giorgi U, et al. Atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent, or recurrent cervical cancer (BEATcc): a randomised, open-label, phase 3 trial. The Lancet. 2024 Jan;403(10421):31–43. — The Lancet
Gladieff L, Martínez-García J, et al. BEATcc (722P): Long-term patient-reported outcomes with atezolizumab plus bevacizumab and chemotherapy for metastatic, persistent or recurrent cervical cancer — BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030) randomised phase 3 trial. Poster. European Society for Medical Oncology (ESMO) Congress 2024. — Ann Oncol (Suppl)
Badiola LB, Milagro NL, Lavín DC, Peraita SL, Ibarbia MA, Kareaga MM, et al. RENO Study: Clinical characteristics, treatment patterns and survival results in patients with metastatic renal cell carcinoma in Northern Spain. Semin Oncol. marzo de 2024;S0093775424000058. — Semin Oncol
Gutiérrez Pérez C, Lastra Aras E, Saiz López P, García Toro E, Blanco Abad C, Rodríguez Ledesma I, et al. Single-center analysis of a real-world cohort of patients with metastatic urothelial carcinoma evaluated by NGS: molecular landscape and efficacy of targeted therapies. Clin Transl Oncol [Internet]. 15 de agosto de 2024 [citado 5 de septiembre de 2024]; Disponible en: https://link.springer.com/10.1007/s12094-024-03651-w — Clin Transl Oncol
Durán I, et al. BladderGATE: Real-world outcomes with atezolizumab in urothelial carcinoma. Poster. American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium 2024. — J Clin Oncol (Suppl)
Juan Fita, M.J.; Anido Herranz, U.; Mendez-Vidal, M.J.; Gironés-Sarrió, R.; Muñoz-Langa, J.; Sepúlveda-Sánchez, J.; Mellado, B.; Alvarez-Fernandez, C.; Heras López, L.; López-Guerrero, J.A.; et al. Phase II Trial Evaluating Olaparib Maintenance in Patients with Metastatic Castration-Resistant Prostate Cancer Responsive or Stabilized on Docetaxel Treatment: SOGUG-IMANOL Study. Cancers 2023, 15, 5223. https://doi.org/10.3390/cancers15215223 — Cancers
Cepeda-Piorno FJ, Puertas B, Albert Croé F, et al. GEM-KYCYDEX renal sub-study: Cystatin-C and creatinine needed to improve management of myeloma-related renal impairment. Poster. American Society of Hematology (ASH) Annual Meeting. — Blood (Suppl)
Nadal E, Álvarez C, Arasanz H, et al. ORIGEN (1278P): Multicenter study on the prevalence of EGFR gene mutations in patients with early-stage resectable non-small cell lung cancer (NSCLC) in Spain. Poster. European Society for Medical Oncology (ESMO) Congress 2023. — Ann Oncol (Suppl)
Garcia-Carbonero R, González Astorga B, Vidal Tocino R, Contreras Toledo D, Pericay C, Fernández Montes A, et al. Real-world study on microsatellite instability and mismatch repair deficiency testing patterns among patients with metastatic colorectal cancer in Spain. Clin Transl Oncol [Internet]. 2023 Aug 31; Available from: https://doi.org/10.1007/s12094-023-03309-z — Clin Transl Oncol
López Muñoz AM, et al. RE-SEARCH: Real-world evidence in colorectal cancer with regorafenib. Publication. — Clin Transl Oncol
Macarulla T, et al. NUMANTIA (331P): Nab-paclitaxel plus gemcitabine in patients with advanced pancreatic cancer — updated results. Poster. European Society for Medical Oncology (ESMO) Congress. — Ann Oncol (Suppl)
Garcia-Donas J, Hurtado A, Garrigos L, Santaballa A, Redondo A, Vidal L, et al. Open-label phase II clinical trial of ketoconazole as CYP17 inhibitor in metastatic or advanced non-resectable granulosa cell ovarian tumors: the GREKO (GRanulosa Et KetOconazole) trial, GETHI 2011-03. Clin Transl Oncol [Internet]. 28 de enero de 2023 — Clin Transl Oncol
González-Martín A, et al. ANITA (LBA37): Atezolizumab combined with platinum-based chemotherapy and maintenance niraparib for recurrent ovarian cancer — primary analysis of the double-blind placebo-controlled ENGOT-Ov41/GEICO 69-O/ANITA phase 3 trial. Poster. European Society for Medical Oncology (ESMO) Congress 2023. — Ann Oncol (Suppl)
Oaknin A, et al. BEATcc: Primary results of BEATcc (ENGOT-Cx10/GEICO 68-C/JGOG1084/GOG-3030), a randomised phase III trial of first-line atezolizumab combined with a platinum doublet and bevacizumab for metastatic, persistent or recurrent cervical cancer. Oral presentation. ESMO Virtual Plenary, 3 November 2023. — Ann Oncol (Suppl)
Ríos-Tamayo R, Soler JA, García-Sánchez R, Pérez Persona E, Arnao M, García-Guiñón A, et al. A glimpse into relapsed refractory multiple myeloma treatment in real-world practice in Spain: the GeminiS study. Hematology. 31 de diciembre de 2023;28(1):2178997 — Hematology
Mellado B, et al. SOGUG-IMANOL: Abstract 168. A phase II study of nivolumab plus ipilimumab in patients with enzalutamide-resistant metastatic castration-resistant prostate cancer. Poster presentation. — Cancers
Morales-Barrera R, et al. EBANO: Real-world evidence of enfortumab vedotin in urothelial carcinoma. ESMO Real-World Data and Digital Oncology Congress. — ESMO RWDDO
Portel L, Fabry-Vendrand C, Texier N, Schwartz D, Capdepon A, Thabut G, Debrieuve D. Characteristics of severe non-eosinophilic asthma: analysis of data from 1075 patients included in the FASE-CPHG study. Journal of Asthma and Allergy. 2023;16:9-21. — Journal of Asthma and Allergy
Fayoux P, Dinomais M, Shaw H, Probert N, Villain F, Pouchain D, Texier N, Auvin S. Randomised, double-blind, placebo-controlled trial of glycopyrronium in children and adolescents with severe sialorrhoea and neurodisabilities: protocol of the SALIVA trial. BMJ Paediatr Open. 2023 May;7. — BMJ Paediatr Open
Basterretxea Badiola L, et al. RENO Study: Clinical characteristics, treatment patterns and survival results in patients with metastatic renal cell carcinoma in Northern Spain. Poster. SEOH (Sociedad Española de Oncología y Hematología) Annual Meeting. — Seminars in Oncology (Suppl)
Rodriguez-Vida A, et al. ABACUS (2393P): Long-term follow-up of neoadjuvant atezolizumab in muscle-invasive bladder cancer. Poster. European Society for Medical Oncology (ESMO) Congress 2023. — Ann Oncol (Suppl)
Morales-Barrera R, et al. EBANO (2382P): Real-world study of enfortumab vedotin in advanced urothelial carcinoma. Poster. European Society for Medical Oncology (ESMO) Congress 2023. — Ann Oncol (Suppl)
Morales-Barrera R, et al. EBANO: Real-world study of enfortumab vedotin in advanced urothelial carcinoma. Poster. SEOM (Sociedad Española de Oncología Médica) Annual Meeting 2023. — Clin Transl Oncol (Suppl)
Powles T, et al. ABACUS-2 (2363MO): Neoadjuvant atezolizumab in combination with olaparib in muscle-invasive bladder cancer. Mini-oral. European Society for Medical Oncology (ESMO) Congress 2023. — Ann Oncol (Suppl)
Hulin C, Perrot A, Macro M, A. Vekhoff, X. Leleu, L. Karlin, S. Manier, L. Vincent, A. El Yamani, W. Abarah, R. Kaphan, C. Zarnitsky, D. Re, L. Christophe, O. Fitoussi, N. Texier, R. Germain, M. Willaime, O. Decaux. Retreatment of patients with anti CD38-based combinations in multiple myeloma in real-life: results from the EmmY cohort study. Blood. 2022;ASH Abstract Poster. — Blood
Mangues-Bafalluy I, et al. LOADH (P-185): Quality of life and adherence to oral antineoplastics in non-small cell lung cancer — LOADH study. Poster. National Congress of Medical Oncology, Hematology and Oncohematological Pharmacy 2022. — Clin Transl Oncol (Suppl)
Perrot A, Decaux O, Farge A, Caillot D, Royer B, Belhadj K, Frenzel L, Sonntag C, Slama B, Bourgeois E, Eveillard JR, Voillat L, Luycx O, Moreau P, Pica GM, Garlantezec R, Germain R, Texier N, Deal C, Hulin C. Bénéfices associés à une prise en charge par autogreffe de cellules souches chez des patients atteints de myélome multiple nouvellement diagnostiqués à 65 ans et au-delà : données en vie réelle, cohorte EMMY. Congrès de la Société Française d’Hématologie. 2022. — Congrès SFH
Montagni I, Pouymayou A, Pereira E, Tzourio C, Schück S, Texier N, González-Caballero JL; CONFINS Group. Measuring Digital Vaccine Literacy: Development and Psychometric Assessment of the Digital Vaccine Literacy Scale. J Med Internet Res. 2022;24(12). — J Med Internet Res
Montagni I, Ouazzani-Touhami K, Pouymayou A, Pereira E, Texier N, Schück S, Tzourio C; CONFINS Group. Who is hesitant about Covid-19 vaccines? The profiling of participants in a French online cohort. Rev Epidemiol Sante Publique. 2022;70(3):123-131. — Rev Epidemiol Sante Publique
Martínez‑López J, Montesinos P, López‑Muñoz N, Ayala R, Martínez‑Sánchez P, Gorrochategui J, Rojas‑Rudilla JL, Primo D, Bergua‑Burgues J, Calbacho M, Calbacho M, et al: Biomarker‑driven phase Ib clinical trial of OPB‑111077 in acute myeloid leukemia. Med Int 2: 7, 2022 — Med Int
Macalli M, Kinouani S, Texier N, Schück S, Tzourio C. Contribution of perceived loneliness to suicidal thoughts among French university students during the COVID-19 pandemic. Sci Rep. 2022 Oct 7;12(1):16833. — Sci Rep
Charle-Maachi C, Moreau-Gaudry A, Sainati D, Camus D, Adenot I, Barthelemy CE, de Chalus T, Debroucker F, Denis F, Gourio C, Habran E, Kamal N, Le Douarin YM, Rosier A, Schuck S, Thébaut JF, Trancart A, Vercamer V. Les solutions numériques en santé, quelles valeurs apportées, quels mécanismes de financement et quelles évaluations ? Therapie. 2022 Jan-Feb;77(1):117-132. — Therapie
Paz-Ares L, et al. CANTABRICO (1532P): Durvalumab plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CANTABRICO): a Spanish Phase IIIb single arm, real-world study. Poster. European Society for Medical Oncology (ESMO) Congress 2022. — Ann Oncol (Suppl)
Nadal E, Álvarez C, Arasanz H, et al. ORIGEN (PD-50): Multicenter study on the prevalence of EGFR gene mutations in patients with early-stage resected non-squamous NSCLC in Spain. Poster. SEOM (Sociedad Española de Oncología Médica) Annual Meeting 2022. — Clin Transl Oncol (Suppl)
Mangues-Bafalluy I, Bernardez B, et al. LOADH (Poster 523): Adherence to oral antineoplastics in patients with non-small cell lung cancer in Spain. Poster. 67th National Congress SEFH 2022. — Farm Hosp (Suppl)
Perrot A, Decaux O, Royer B, Caillot D, Belhadj K, Farge A, Frenzel L, Sonntag C, Slama B, Bourgeois-Petit E, Moreau P, Voillat L, Luycx O, Benboubker L, Pica GM, Maloisel F, Eveillard JR, Algrin C, Schmitt A, Garlantezec R, Texier N, Germain R, Willaime M, Hulin C. What is the benefit of autologous stem cell transplantation in multiple myeloma beyond the age of 65? Inputs from real-world data in the EmmY cohort. Blood. 2022;ASH Abstract Poster. — Blood
Moya-Alarcón C, Piera G, Callejo Á, Gascó A. Real-world treatment patterns and outcomes in platinum-sensitive recurrent high-grade serous ovarian cancer patients. Journal of Comparative Effectiveness Research. 2022 Jan;11(1):13-27. DOI: 10.2217/cer-2021-0135. PMID: 34697945. — Journal of Comparative Effectiveness Research
Grande E, Alonso-Gordoa T, Reig O, Esteban E, Castellano D, Garcia-Del-Muro X, Mendez MJ, García-Donas J, González Rodríguez M, Arranz-Arija JA, Lopez-Criado P, Molina-Cerrillo J, Mellado B, Alvarez-Fernandez C, De Velasco G, Cuéllar-Rivas MA, Rodríguez-Alonso RM, Rodríguez-Moreno JF, Suarez-Rodriguez C. Results from the INMUNOSUN-SOGUG trial: a prospective phase II study of sunitinib as a second-line therapy in patients with metastatic renal cell carcinoma after immune checkpoint-based combination therapy. ESMO Open. 2022 Apr;7(2):100463. doi: 10.1016/j.esmoop.2022.100463. Epub 2022 Apr 8. PMID: 35405437; PMCID: PMC9058923. — ESMO Open
Lamia B, Dallongeville J, Bensimon L, Hakme A, Bénard N, Lévy-Bachelot L, Pouriel M, Sitbon O. Riociguat real-world use in patients with chronic thromboembolic pulmonary hypertension: a retrospective, observational cohort study in France. Respiratory Medicine and Research. 2022;p. 100987. — Respiratory Medicine and Research
Zapatero A, Guerrero A, Maldonado X, Álvarez A, San-Segundo CG, Rodríguez MÁC, Solé JM, Olivé AP, Casas F, Boladeras A, de Vidales CM, de la Torre MLV, Vara S, Sanz JL, Calvo FA. High-dose radiotherapy and risk-adapted androgen deprivation in localised prostate cancer (DART 01/05): 10-year results of a phase 3 randomised, controlled trial. Lancet Oncol. 2022 May;23(5):671-681. doi: 10.1016/S1470-2045(22)00190-5. Epub 2022 Apr 12. PMID: 35427469. — Lancet Oncol
Bernadett Szabados, Mark Kockx, Zoe June Assaf, Pieter-Jan van Dam, Alejo Rodriguez-Vida, Ignacio Duran, Simon J. Crabb, Michiel S. Van Der Heijden, Albert Font Pous, Gwenaelle Gravis, Urbano Anido Herranz, Andrew Protheroe, Alain Ravaud, Denis Maillet, Maria Jose Mendez, Cristina Suarez, Mark Linch, Aaron Prendergast, Charlotte Tyson, Diana Stanoeva, Sofie Daelemans, Miche Rombouts, Sanjeev Mariathasan, Joy S. Tea, Kelly Mousa, Shruti Sharma, Alexey Aleshin, Romain Banchereau, Daniel Castellano, Thomas Powles,
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder. European Urology, 2022. — European Urology
Castellano D, Durán I, Méllado B, et al. NICARAGUA (2366P): Phase I-II study of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer. Poster. European Society for Medical Oncology (ESMO) Congress 2022. — Ann Oncol (Suppl)
Climent MA, Font A, Durán I, Puente J, José Méndez-Vidal M, Sáez MI, et al. A phase II randomised trial of abiraterone acetate plus prednisone in combination with docetaxel or docetaxel plus prednisone after disease progression to abiraterone acetate plus prednisone in patients with metastatic castration-resistant prostate cancer: The ABIDO-SOGUG trial. Eur J Cancer. noviembre de 2022;175:110-9. — Eur J Cancer
Davies A, Cinieri S, Dupoiron D, España Fernandez S, Leclerc J, Montesarchio V, Mystakidou K, Serna J, Tack J, On Behalf Of The Nacasy Study Group. A Prospective, Real-World, Multinational Study of Naloxegol for Patients with Cancer Pain Diagnosed with Opioid-Induced Constipation-The NACASY Study. Cancers (Basel). 2022 Feb 23;14(5):1128. doi: 10.3390/cancers14051128. PMID: 35267436; PMCID: PMC8909554. — Cancers (Basel)
Villarroel PG, Padró JG, Marquina G, Jáñez NM, González EE, Antón A, et al. Increased quality of life in patients with breakthrough cancer pain after individualized therapy: the CAVIDIOM study. Future Oncol. noviembre de 2022;18(35):3913-27. — Future Oncol
Ramírez-Daffós P, Jiménez-Orozco E, Bolaños M, González Astorga B, Rubiales S, Ceballos-Barbancho E, et al. A phase 2 study for evaluating doxycycline 50 mg once daily and 100 mg once daily as preemptive treatment for skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy. Support Care Cancer. octubre de 2022;30(10):8081-8. — Support Care Cancer
Ramírez-Daffós P, et al. DERMIA-SKIN TOX: Dermatological toxicities associated with anti-EGFR therapy in colorectal cancer. Poster. SEOM (Sociedad Española de Oncología Médica) Annual Meeting 2021. — Clin Transl Oncol (Suppl)
Decaux O, Perrot A, Frenzel L, Royer B, Belhadj K, Moreau P, Caillot D, Leleu X, Farge A, Vekhoff A, Schulmann S, Fontan J, Orsini F, Sanhes L, Richez V, Jaccard A, Garlantezec R, Texier N, Germain R, Boccaccio C, Hulin C. RD Vs. VRD: What Is the First-Line Real-Life Management of Multiple Myeloma Patients Ineligible for Stem Cell Auto Transplantation in the Emmy Cohort? Blood. 2021;ASH Abstract Poster. — Blood
Decaux O, Frenzel L, Royer B, Belhadj K, Perrot A, Caillot D, Leleu X, Farge A, Vekhoff A, Schulmann S, Garlantezec R, Texier N, Willaime M, Nobili Escriva C, Boccaccio C, Hulin C. RD vs VRD : quelle prise en charge en première ligne en vie réelle pour les patients atteints de myélome multiple non éligibles à une autogreffe de cellules souches dans la cohorte EMMY ? Congrès de la Société Française d’Hématologie. 2021. — Congrès SFH
Perrot A, Hulin C, Macro M, Frenzel L, Araujo C, Moreau P, Royer B, Belhadj K, Caillot D, Leleu X, Vekhoff A, Schulmann S, Manier S, Karlin L, Vincent L, Rigaudeau S, Chaoui D, Garlantezec R, Texier N, Willaime M, Boccaccio C, Decaux O. Real-Life Survival Data after Triple-Exposure to Proteasome Inhibitors (PI), Immunomodulators (IMID) and Anti-CD38 in Multiple Myeloma Patients in the Emmy Cohort. Blood. 2021;ASH Abstract Poster. — Blood
Decaux O, Frenzel L, Royer B, Belhadj K, Perrot A, Caillot D, Leleu X, Farge A, Vekhoff A, Schulmann S, Garlantezec R, Texier N, Willaime M, Nobili Escriva C, Boccaccio C, Hulin C. Therapeutic management of multiple myeloma and healthcare resource assessment by matching the EMMY cohort to the data of the National Health Data System (SNDS) in France. ISPOR Europe. 2021. — ISPOR Europe
Arsandaux J, Montagni I, Macalli M, Texier N, Pouriel M, Germain R, Mebarki A, Kinouani S, Tournier M, Schück S, Tzourio C. Mental health condition of college students compared to non-students during COVID-19 lockdown: the CONFINS study. BMJ Open. 2021 Aug 19;11(8):e053231. — BMJ Open
Feliu J, Jorge Fernández M, Macarulla T, et al. Phase II clinical trial of nab-paclitaxel plus gemcitabine in elderly patients with previously untreated locally advanced or metastatic pancreatic adenocarcinoma: BIBABRAX study. Cancer Chemother Pharmacol, 87(4):543-553, 15 Jan 2021 — Cancer Chemother Pharmacol
Paz-Ares L, Arriola E, Garcia MR, et al. CANTABRICO: Durvalumab plus platinum-etoposide in extensive-stage small-cell lung cancer — SEOM 2021 poster. Poster. SEOM (Sociedad Española de Oncología Médica) Annual Meeting 2021. — Clin Transl Oncol (Suppl)
Garcia-Carbonero R, et al. COMISH: Real-world outcomes with checkpoint inhibitors in microsatellite instability-high colorectal cancer. Poster. SEOM (Sociedad Española de Oncología Médica) Annual Meeting 2021. — Clin Transl Oncol (Suppl)
Tuca Rodríguez A, Núñez Viejo M, Maradey P, Canal-Sotelo J, Guardia Mancilla P, Gutiérrez Rivero S, et al. Impact of individualized management of breakthrough cancer pain on quality of life in advanced cancer patients: CAVIDIOPAL study. Support Care Cancer. agosto de 2021;29(8):4799-807. — Support Care Cancer
Scotte F, Simon H, Laplaige P, Antoine EC, Spasojevic C, Texier N, Gouhier K, Chouaid C. Febrile neutropenia prophylaxis, G-CSF physician preferences: discrete-choice experiment. BMJ Support Palliat Care. 2021. — BMJ Support Palliat Care
Hernanz de Lucas R, Núñez Fernández M, Gómez-Caamaño A, et al. Quality of life in patients with breakthrough cancer pain in radiation oncology departments in Spain: the CAVIDIOR study. Future Oncol. 2021. — Future Oncol
A. Zapatero, A. Álvarez, A. Guerrero, X. Maldonado, C. González, MA. Cabeza, C. Martín, et al. Prognostic value of testosterone castration levels following androgen deprivation and high-dose radiotherapy in localized prostate cancer: Results from a phase III trial. Radiotherapy and Oncology 160 (2021) 115–119. https://doi.org/10.1016/j.radonc.2021.04.018 — Radiother Oncol
Montagni I, Ouazzani-Touhami K, Mebarki A, Texier N, Schück S, Tzourio C; CONFINS group. Acceptance of a Covid-19 vaccine is associated with ability to detect fake news and health literacy. J Public Health (Oxf). 2021 Mar 9:fdab028. — J Public Health
De Lucas RH, Fernández MN, Gómez-Caamaño A, López RM, De La Torre IF, La Torre Tomás AD, et al. Quality of life in patients with breakthrough cancer pain in radiation oncology departments in Spain: the CAVIDIOR study. Future Oncol. marzo de 2021;17(8):943-54. — Future Oncol
Castellano D, et al. DUTRENEO: Durvalumab plus tremelimumab in neoadjuvant setting for muscle-invasive bladder cancer (MIBC). Oral presentation. American Society of Clinical Oncology (ASCO) Annual Meeting 2020. — J Clin Oncol (Suppl)
Oaknin A, Iglesias-González M, Alarcón J, et al. ATOMICC (880TiP): Randomized, open-label, phase II trial of dostarlimab (TSR-042) as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemo-radiation. Poster. European Society for Medical Oncology (ESMO) Virtual Congress 2020. — Ann Oncol (Suppl)
Dupoiron D, Montesarchio V, Leclerc J, et al. NACASY (1866P): Preliminary quality of life and safety results of naloxegol for patients with cancer pain diagnosed with opioid-induced constipation. Poster. European Society for Medical Oncology (ESMO) Virtual Congress 2020. — Ann Oncol (Suppl)
Davies A, Tack J, Fernandez A, et al. NACASY: Naloxegol for patients with cancer pain diagnosed with opioid-induced constipation (OIC) — NACASY observational study. Abstract. American Society of Clinical Oncology (ASCO) Annual Meeting 2020. — J Clin Oncol (Suppl)
Climent MA, Font A, Durán I, et al. ABIDO-SOGUG: Abiraterone in patients with bone metastases mCRPC. Poster. American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium 2020. — J Clin Oncol (Suppl)
Durán I, et al. BladderGATE: A phase II study of atezolizumab in patients with locally advanced or metastatic urothelial carcinoma. Poster. American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium 2020. — J Clin Oncol (Suppl)
Grande E, Alonso T, Reig O, et al. INMUNOSUN-SOGUG (Abstract #5060): A prospective phase II study of sunitinib as second-line treatment in patients with metastatic renal cell cancer after immunotherapy-based combination upfront. Poster. American Society of Clinical Oncology (ASCO) Annual Meeting 2020. — J Clin Oncol (Suppl)
Duran I, et al. NEODURVARIB: Neoadjuvant durvalumab plus olaparib in muscle-invasive urothelial bladder cancer. Poster. European Society for Medical Oncology (ESMO) Virtual Congress 2020. — Ann Oncol (Suppl)
Duran I, et al. NEODURVARIB: Neoadjuvant durvalumab plus olaparib in muscle-invasive urothelial bladder cancer. Poster. American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium 2020. — J Clin Oncol (Suppl)
Powles T, et al. ABACUS: Neoadjuvant atezolizumab in muscle-invasive bladder cancer — updated results. Poster. European Society for Medical Oncology (ESMO) Asia Congress 2020. — Ann Oncol (Suppl)
Martin Sebente MC, Carretero A, De Velasco G, et al. Immune checkpoint inhibitors (ICIs) plus tyrosine kinase inhibitors (TKIs) combination in the first-line setting of metastatic clear cell renal cell carcinoma: A meta-analysis of randomized clinical trials (Abstract #287855). Poster. American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium 2020. — J Clin Oncol (Suppl)
Van Ganse E, Texier N, Dima AL, Belhassen M, Laforest L, Herbage S, Schück S, Hernandez G, Garin O, Ferrer M, de Bruin M; ASTRO-LAB group. Effects of short- and long-acting beta-agonists on asthma exacerbations: a prospective cohort. Ann Allergy Asthma Immunol. 2020 Mar;124(3):254-260. — Ann Allergy Asthma Immunol
Feliu J, Macarulla T, et al. BIBABRAX: Nab-paclitaxel plus gemcitabine in elderly patients with advanced pancreatic cancer. Poster. American Society of Clinical Oncology (ASCO) Annual Meeting 2020. — J Clin Oncol (Suppl)
Vera R, et al. RESUNET (1174P): Real-world use of nab-paclitaxel plus gemcitabine in pancreatic cancer. Poster. European Society for Medical Oncology (ESMO) Virtual Congress 2020. — Ann Oncol (Suppl)
Aranda, E., Polo, E., Camps, C. et al. Treatment patterns for metastatic colorectal cancer in Spain. Clin Transl Oncol 22, 1455–1462 (2020). https://doi.org/10.1007/s12094-019-02279-5 — Clin Transl Oncol
Iglesias Docampo L, Taberna M, Gutiérrez Calderón V, et al. NIVOTAX (TTCC-2019-01): Experience launching a clinical trial in COVID-19 context — phase II randomized study of nivolumab plus paclitaxel in first-line recurrent/metastatic HNSCC not eligible for cisplatin-based chemotherapy. Oral presentation. SEOM (Sociedad Española de Oncología Médica) Annual Meeting 2020. — Clin Transl Oncol (Suppl)
Ciruelos E, Prat A, et al. TATEN Trial: Targeting non-luminal disease by PAM50 with pembrolizumab plus paclitaxel in HR-positive/HER2-negative advanced/metastatic breast cancer after CDK 4/6 inhibitor treatment. Poster. San Antonio Breast Cancer Symposium (SABCS) 2020. — Cancer Res (Suppl)
Saura C, Prat A, Ciruelos E, et al. NEREA Trial: Targeting EGFR/ERBB2 with neratinib in hormone receptor (HR)-positive/HER2-negative HER2-enriched advanced/metastatic breast cancer. Poster. San Antonio Breast Cancer Symposium (SABCS) 2020. — Cancer Res (Suppl)
Vicente-Baz D, Paredes A, Morán T, Massuti B, Reguart N, Álvarez R, et al. ASTRIS, a large real-world study to evaluate the efficacy of osimertinib in epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer patients: Clinical characteristics and genotyping methods in a Spanish cohort. Rev Esp Patol. julio de 2020;53(3):140-8. — Rev Esp Patol
Ruano D, López-Martín JA, Moreno L, Lassaletta Á, Bautista F, Andión M, et al. First-in-Human, First-in-Child Trial of Autologous MSCs Carrying the Oncolytic Virus Icovir-5 in Patients with Advanced Tumors. Mol Ther. abril de 2020;28(4):1033-42. — Mol Ther
Gnassounou R, Défontaines B, Denolle S, Brun S, Schück S, Germain R, Schwartz D, Cacciamani F, Michon A, Belin C, Mailler D. Validation of a videoconference-based neuropsychological assessment: The e-COG study. Alzheimers Dement. 2020;16:e047330. — Alzheimer's Dement
Decaux O, Frenzel L, Garlantezec R, Macro M, Belhadj K, Perrot A, Germain R, Texier N, Willaime M, Nobili Escriva C, Boccaccio C, Hulin C. Etude EmmY : Caractéristiques des patients atteints de myélome multiple et prise en charge thérapeutique en première ligne en vie réelle en France. Congrès de la société française d'hématologie, 2020, Paris. Communication orale. — Revue de la Société Française d'Hématologie
Martínez-López J, Montesinos P, López-Muñoz N, et al. FASE I EN LMA-Otsuka: Biomarker-driven phase Ib clinical trial of OPB111077 in acute myeloid leukemia increases overall response rates. Poster. American Society of Hematology (ASH) Annual Meeting 2020. — Blood (Suppl)
Lozano, María Luisa et al. “A decade of changes in management of immune thrombocytopenia, with special focus on elderly patients.” Blood cells, molecules & diseases 86 (2020): 102505 . — Blood Cells Mol Dis
Eva Ciruelos, María Apellániz‐Ruiz, Blanca Cantos, Noelia Martinez‐Jáñez, Coralia Bueno‐Muiño, Maria‐Jose Echarri, Santos Enrech, Juan‐Antonio Guerra, Luis Manso, Tomas Pascual, Cristina Dominguez, Juan‐Francisco Gonzalo, Juan‐Luis Sanz, Cristina Rodriguez‐Antona, Juan‐Manuel Sepúlveda, A Pilot, Phase II, Randomized, Open‐Label Clinical Trial Comparing the Neurotoxicity of Three Dose Regimens of Nab‐Paclitaxel to That of Solvent‐Based Paclitaxel as the First‐Line Treatment for Patients with Human Epidermal Growth Factor Receptor Type 2‐Negative Metastatic Breast Cancer, The Oncologist, Volume 24, Issue 11, November 2019, Pages e1024–e1033, https://doi.org/10.1634/theoncologist.2017-0664 — The Oncologist
González-Martín A, Colombo N, Heitz F, et al. ANITA/ENGOT-Ov41/GEICO-69-O (TPS5599): Phase III randomized, double-blinded trial of platinum-based chemotherapy with/without atezolizumab followed by niraparib maintenance with/without atezolizumab in recurrent ovarian cancer. Poster. American Society of Clinical Oncology (ASCO) Annual Meeting 2019. — J Clin Oncol (Suppl)
Ramírez-Daffós P, et al. DERMIA-SKIN TOX: Dermatological toxicities associated with anti-EGFR therapy in colorectal cancer. Poster. World Congress on Gastrointestinal Cancer (WCGI) 2019. — Ann Oncol (Suppl)
Carrato A, Benavides M, Massutí B, Ferreiro-Monteagudo R, García Alfonso P, Falcó E, Reboredo M, Cano T, Gallego J, Viéitez JM, Layos L, Salud A, Polo E, Dotor E, Durán-Ogalla G, Rodriguez-Garrote M, Calvo A, Grande E, Aranda E. First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD). BMC Cancer. 2019 Jun 3;19(1):533. doi: 10.1186/s12885-019-5753-7. PMID: 31159765; PMCID: PMC6547483. — BMC Cancer
Paz-Ares L, et al. CANTABRICO (1993P): Durvalumab plus platinum-etoposide as first-line treatment of extensive-stage small-cell lung cancer (CANTABRICO): a Spanish real-world study. Poster. European Society for Medical Oncology (ESMO) Congress 2019. — Ann Oncol (Suppl)
Hamdaoui N, David P, Rondeau V, Pouriel M, Agostini A. Compliance with national guidelines for antibiotic prophylaxis prescription with a surgical abortion: Results of the Mya study. J Gynecol Obstet Hum Reprod. 2019 May;48(5):315-317. — J Gynecol Obstet Hum Reprod
Macarulla T, Pazo-Cid R, Guillén-Ponce C, López R, Vera R, Reboredo M, Muñoz Martin A, Rivera F, Díaz Beveridge R, La Casta A, Martín Valadés J, Martínez-Galán J, Ales I, Sastre J, Perea S, Hidalgo M. Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2. J Clin Oncol. 2019 Jan 20;37(3):230-238. — J Clin Oncol
Lozano ML, Mingot-Castellano ME, Perera MM, et al. VERTEX 2.0 (Abstract 2361): Influence of age on treatment with thrombopoietin receptor agonists in patients with immune thrombocytopenia — a retrospective multicenter study. Poster. American Society of Hematology (ASH) Annual Meeting 2019. — Blood (Suppl)
Lozano ML, Mingot-Castellano ME, Perera MM, Jarque I, Campos-Alvarez RM, González-López TJ, Carreño-Tarragona G, Bermejo N, Lopez-Fernandez MF, de Andrés A, Valcarcel D, Casado-Montero LF, Alvarez-Roman MT, Orts MI, Novelli S, Revilla N, González-Porras JR, Bolaños E, Rodríguez-López MA, Orna-Montero E, Vicente V. Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia. Sci Rep. 2019 Nov 13;9(1):16680. doi: 10.1038/s41598-019-53209-y. Erratum in: Sci Rep. 2021 Aug 13;11(1):16867. PMID: 31723222; PMCID: PMC6853922. — Sci Rep
Pérez-Hernández, C., Blasco, A., Gándara, Á. et al. Prevalence and characterization of breakthrough pain in patients with cancer in Spain: the CARPE-DIO study. Sci Rep 9, 17701 (2019). https://doi.org/10.1038/s41598-019-54195-x — Sci Rep
Martínez N, Herrera M, Frías L, Provencio M, Pérez-Carrión R, Díaz V, Morse M, Crespo MC. A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study. Clin Transl Oncol. 2019 Apr;21(4):489-498. doi: 10.1007/s12094-018-1950-0. Epub 2018 Oct 6. PMID: 30293230. — Clin Transl Oncol
Powles, T., Kockx, M., Rodriguez-Vida, A. et al. Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial. Nat Med 25, 1706–1714 (2019). https://doi.org/10.1038/s41591-019-0628-7 — Nat Med
Pérez Hernández C, Blasco Cordellat A, Gándara del Castillo Á, et al. CARPE-DIO: Prevalence and characterization of breakthrough pain in patients with cancer in Spain. Poster. 11th Congress of the European Pain Federation (EFIC) 2019. — Eur J Pain (Suppl)
Davies A, Tack J, Fernández A, et al. NACASY: Observational study of naloxegol for patients with cancer pain diagnosed with opioid-induced constipation — preliminary results. Poster. 11th Congress of the European Pain Federation (EFIC) 2019. — Eur J Pain (Suppl)
Rodriguez-Vida A, Castellano D, Climent MA, et al. NICARAGUA: Phase I/II study of niraparib plus cabozantinib in patients with advanced kidney/urothelial carcinoma. Preliminary data of phase I. Poster. American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium 2019. — J Clin Oncol (Suppl)
Castellano D, et al. DUTRENEO: Durvalumab plus tremelimumab in neoadjuvant setting for muscle-invasive bladder cancer. Poster. American Society of Clinical Oncology (ASCO) Annual Meeting 2019. — J Clin Oncol (Suppl)
Duran I, et al. NEODURVARIB: Neoadjuvant durvalumab plus olaparib in muscle-invasive urothelial bladder cancer. Poster. American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium 2019. — J Clin Oncol (Suppl)
Dutilleul A, Morel J, Schilte C, Launay O; les participants à la table ronde « Sujet d'actualité (1) » des Ateliers de Giens XXXIV. Comment améliorer l'acceptabilité vaccinale (évaluation, pharmacovigilance, communication, santé publique, obligation vaccinale, peurs et croyances). Therapie. 2019 Feb;74(1):119-129. — Therapie
Dutilleul A, Morel J, Schilte C, Launay O; participants of Giens XXXIV Round Table 'hot topic No. 1'. How to improve vaccine acceptability (evaluation, pharmacovigilance, communication, public health, mandatory vaccination, fears and beliefs). Therapie. 2019 Feb;74(1):131-140. — Therapie
Hernandez G, Garin O, Dima AL, Pont A, Martí Pastor M, Alonso J, Van Ganse E, Laforest L, de Bruin M, Mayoral K, Serra-Sutton V, Ferrer M; ASTRO-LAB Group. EuroQol (EQ-5D-5L) Validity in Assessing the Quality of Life in Adults With Asthma: Cross-Sectional Study. J Med Internet Res. 2019 Jan 23;21(1):e10178. — J Med Internet Res
Van Ganse E, Texier N, et al. Que nous disent les asthmatiques sur leurs exacerbations sévères ? Therapie. 2019 Feb;74(1):119-129. — Therapie
Raherison C, Decuypere L, Pouriel M, Roche N. Does Gender Influence Adherence to Inhaled Therapy in COPD? An Observational Study of Patients Treated with Indacaterol/Glycopyrronium 110/50 ug o.d. (IND/GLY). American Thoracic Society, 2019. Poster. — Poster
Climent MA, Font A, Durán I, et al. ABIDO-SOGUG: A phase II study of abiraterone acetate in patients with metastatic castration-resistant prostate cancer with bone metastases. Poster. European Society for Medical Oncology (ESMO) Congress 2018. — Ann Oncol (Suppl)
Vela M, Corral D, Carrasco P, Fernández L, Valentín J, González B, et al. Haploidentical IL-15/41BBL activated and expanded natural killer cell infusion therapy after salvage chemotherapy in children with relapsed and refractory leukemia. Cancer Lett. mayo de 2018;422:107-17. — Cancer Lett
Ramirez M, et al. CELYVIR: First-in-child trial of Celyvir (autologous mesenchymal stem cells carrying the oncolytic virus ICOVIR-5) in patients with relapsed and refractory pediatric solid tumors. Poster. American Society of Clinical Oncology (ASCO) Annual Meeting 2018. — J Clin Oncol (Suppl)
Fernández L, Leivas A, Valentín J, Escudero A, Corral D, De Paz R, et al. How do we manufacture clinical‐grade interleukin‐15–stimulated natural killer cell products for cancer treatment? Transfusion (Paris). junio de 2018;58(6):1340-7. — Transfusion (Paris)
López Polo E, et al. STREAM: Second-line treatment of metastatic colorectal cancer in a real-world setting. Poster. SEOM (Sociedad Española de Oncología Médica) Annual Meeting 2018. — Clin Transl Oncol (Suppl)
Carles, J.; Castellano, D.; Méndez-Vidal, M.J.; Mellado, B.; Saez, M.I.; González Del Alba, A.; Perez-Gracia, J.L.; Jimenez, J.; Suárez, C.; Sepúlveda, J.M.; et al. Circulating Tumor Cells as a Biomarker of Survival and Response to Radium-223 Therapy: Experience in a Cohort of Patients With Metastatic Castration-Resistant Prostate Cancer. Clin. Genitourin. Cancer 2018, 16, e1133–e1139. — Clin Genitourin Cancer
Arriola E, García Gómez R, Diz P, Majem M, Martínez Aguillo M, Valdivia J, et al. Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain. BMC Cancer. diciembre de 2018;18(1):106. — BMC Cancer
Rodriguez-Vida A, Castellano D, Climent MA, et al. NICARAGUA: A phase I/II study of niraparib plus cabozantinib in patients with advanced urothelial/kidney cancer. Poster. American Society of Clinical Oncology (ASCO) Annual Meeting 2018. — J Clin Oncol (Suppl)
Powles T, et al. ABACUS: Neoadjuvant atezolizumab in muscle-invasive bladder cancer. Poster. American Society of Clinical Oncology (ASCO) Annual Meeting 2018. — J Clin Oncol (Suppl)
Powles T, Kockx M, Rodriguez-Vida A, et al. ABACUS: Neoadjuvant atezolizumab in cisplatin-ineligible muscle-invasive bladder cancer. Poster. European Society for Medical Oncology (ESMO) Congress 2018. — Ann Oncol (Suppl)
de Bruin M, Dima AL, Texier N, van Ganse E; ASTRO-LAB group. Explaining the Amount and Consistency of Medical Care and Self-Management Support in Asthma: A Survey of Primary Care Providers in France and the United Kingdom. J Allergy Clin Immunol Pract. 2018 Nov-Dec;6(6):1916-1925.e7. — J Allergy Clin Immunol Pract
Roche N, Le Gros V, Pouriel M, Decuypere L, Raherison C. Observational study of adherence to indacaterol/glycopyrronium 110/50µg o.d. (IND/GLY) in COPD. ERS International Congress 2018. — Eur Respir J (Suppl)
Le Rouzic O, Roche N, Cortot AB, Tillie-Leblond I, Masure F, Perez T, Boucot I, Hamouti L, Ostinelli J, Pribil C, Poutchnine C, Schück S, Pouriel M, Housset B. Defining the 'Frequent Exacerbator' Phenotype in COPD: A Hypothesis-Free Approach. Chest. 2018 May;153(5):1106-1115. — Chest
Le Rouzic O, Roche N, Cortot A, Masure F, Perez T, Boucot I, Piedbois P, Ostinelli J, Poutchnine C, Pribil C, Schück S, Pouriel M, Housset B. ESOD : un score issu de la cohorte EXACO pour identifier les patients à risque d'exacerbations fréquentes. CLPF 2017. Poster. — Poster
Dima AL, van Ganse E, Laforest L, Texier N, de Bruin M; The Astro-Lab Group. Measuring medication adherence in asthma: Development of a novel self-report tool. Psychol Health. 2017 Oct;32(10):1288-1307. — Psychol Health
Conteduca V, Wetterskog D, Sharabiani MTA, Grande E, Fernandez-Perez MP, Jayaram A, et al. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study. Ann Oncol. julio de 2017;28(7):1508-16. — Ann Oncol
Climent M.Á. Pérez-Valderrama B. Mellado B. Fernández Parra E.M. Fernández Calvo O. Ochoa de Olza M. et al. Weekly cabazitaxel plus prednisone is effective and less toxic for “unfit” metastatic castration-resistant prostate cancer: phase II Spanish Oncology Genitourinary Group (SOGUG) trial. Eur J Cancer. 2017 Nov 2; 87: 30-37 — Eur J Cancer
David P, Rondeau V, Pouriel M, Agostini A. Cervical preparation prior to surgical abortion in real-life conditions and factors driving the prescription: A national observational study. J Gynecol Obstet Hum Reprod. 2017 Dec;46(10):715-719. — J Gynecol Obstet Hum Reprod
Lozano, M.L., Revilla, N., Gonzalez-Lopez, T.J. et al. Real-life management of primary immune thrombocytopenia (ITP) in adult patients and adherence to practice guidelines. Ann Hematol 95, 1089–1098 (2016). https://doi.org/10.1007/s00277-016-2665-3 — Ann Hematol
Bover I, Colombo N, Korach J, Davis KL, Kaye JA, Lewis JRR, et al. Treatment patterns and BRCA testing practices in platinum-sensitive recurrent serous ovarian cancer: a Spanish medical record review. Ann Oncol. octubre de 2016;27:vi302. — Ann Oncol
Mellado B, Gutierrez Calderón V, López JA, et al. PREMIERE trial: Durvalumab in combination with enzalutamide for metastatic castration-resistant prostate cancer (mCRPC). Poster. European Society for Medical Oncology (ESMO) Congress 2016. — Ann Oncol (Suppl)
Bover J, Colombo N, Korach J, et al. Treatment patterns and BRCA testing practices in platinum-sensitive recurrent serous ovarian cancer: a Spanish medical record review. Poster. European Society for Medical Oncology (ESMO) Congress 2016. — Ann Oncol (Suppl)
Zapatero A. Guerrero A. Maldonado X. et al. Late radiation and cardiovascular adverse effects after androgen deprivation and high-dose radiation therapy in prostate cancer: results from the DART 01/05 randomized phase 3 trial. Int J Radiat Oncol Biol Phys. 2016; 96:341-348 https://doi.org/10.1016/j.ijrobp.2016.06.2445 — Int J Radiat Oncol Biol Phys
Roche N, Pribil C, Devillier P, Van Ganse E, Schück S, Doussaint J, Martin J, Nachbaur G, Boucot I. Limited treatment adaptation despite poor asthma control in asthma patients treated with inhaled corticosteroids. J Asthma. 2016;53(1):76-85. — J Asthma
Vié le Sage F, Gaudelus J, Lert F, Dufour V, Texier N, Pouriel M, Schück S, Tehard B, Bréart G. Public health impact of Infanrix hexa™ (DTPa-HBV-IPV/Hib) reimbursement: A study programme in France. Part 2: Evolution of the acceptability of infants' vaccination against hepatitis B in general and pediatric practices – the PRALINE study. Rev Epidemiol Sante Publique. 2016 Jun;64(3):185-94. — Rev Epidemiol Sante Publique
Schück S, Texier N, Housset B, Mebarki A, Faviez C, Abdellaoui R, Pouchain D, Roche N. Utilisation de l'analyse vidéo automatisée des gestes dans l'apprentissage de la prise de traitements inhalés : une solution innovante. 20ème congrès de pneumologie de la langue française – Lille, 29-31 Janvier 2016. — Poster
Gaudelus J, Vié le Sage F, Dufour V, Lert F, Texier N, Pouriel M, Tehard B, Bréart G. Public health impact of Infanrix hexa (DTPa-HBV-IPV/Hib) reimbursement: A study programme in France. Part 1: Evolution of hepatitis B vaccine coverage rates in infants aged less than 27 months, in the general population – the PopCorn study. Rev Epidemiol Sante Publique. 2016 Feb;64(1):23-32. — Rev Epidemiol Sante Publique
Leroyer C, Mahé I, Daurès JP, Quéré I, Aubin C, Compagnon A, Doussaint J, Schück S, Pouchain D. Prevention of venous thromboembolic events by fondaparinux 2.5mg in patients hospitalized for an acute medical illness. ArchiMed Study. J Mal Vasc. 2015 Jul;40(4):248-58. — J Mal Vasc
Van Ganse E, Texier N, Dima AL, Laforest L, Ferrer M, Hernandez G, Schuck S, Herbage S, Vial D, de Bruin M; ASTRO-LAB group. Assessment of the safety of long-acting β2-agonists in routine asthma care: the ASTRO-LAB protocol. NPJ Prim Care Respir Med. 2015 Jun 18;25:15040. — NPJ Prim Care Respir Med
Godet C, Laurent F, Béraud G, Toper C, Camara B, Philippe B, Germaud P, Cottin V, Beigelman-Aubry C, Khalil A, Blouin P, Pouriel M, Roblot F, Bergeron A, Cadranel J; ACHROSCAN study group. Phenotyping chronic pulmonary aspergillosis by cluster analysis. Eur Respir J. 2015 Nov;46(5):1509-12. — Eur Respir J
Zapatero A. Guerrero A. Maldonado X. et al. High-dose radiotherapy with short-term or long-term androgen deprivation in localized prostate cancer (DART 01/05 GICOR): A randomized, controlled, phase 3 trial. Lancet Oncol. 2015; 16: 320-327 — Lancet Oncol
Hernández G, Avila M, Pont A, Garin O, Alonso J, Laforest L, Cates CJ, Ferrer M; ASTRO-LAB group. Long-acting beta-agonists plus inhaled corticosteroids safety: a systematic review and meta-analysis of non-randomized studies. Respir Res. 2014 Jul 19;15(1):83. — Respir Res
Reguart N, Rosell R, Cardenal F, Cardona AF, Isla D, Palmero R, et al. Phase I/II trial of vorinostat (SAHA) and erlotinib for non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations after erlotinib progression. Lung Cancer. mayo de 2014;84(2):161-7. — Lung Cancer
Roche N, Pribil C, Van Ganse E, Serrier P, Housset B, Poirier D, Texier N, Schück S, Boucot I. Real-life use of fluticasone propionate/salmeterol in patients with chronic obstructive pulmonary disease: a French observational study. BMC Pulm Med. 2014 Apr 2;14:56. — BMC Pulm Med
Laforest L, Martin J, Licaj I, Devouassoux G, Chatte E, Van Ganse E. Identification dans les bases de l'Assurance Maladie de facteurs associés aux grosses délivrances de bêtas agonistes inhalés à courte durée d'action dans l'asthme. 6ème forum scientifique de pharmaco-épidémiologie. Paris. — Poster
Van Ganse E, Leproust S, Laforest L, Saint-Lary O, Mercier A, Texier N. The ASTRO-LAB project: A European project combining healthcare databases and direct patient follow-up to assess the safety of long-acting ß2 agonists (LABAs) in asthma in routine care. 6ème forum scientifique de pharmaco-épidémiologie. Paris. — Poster
Leproust S, Bréart G, Dufour V, Gaudelus J, Lert F, Vié le Sage F, Théard B. Programme d'étude évaluant l'impact de santé publique du remboursement de la spécialité InfanrixHexa®, en population générale et en médecine générale et pédiatrique. Études pharmaco-épidémiologiques réalisées à la demande des autorités de santé. 6ème forum scientifique de pharmaco-épidémiologie. Paris. — Poster
Parez N, Pozzetto B, Texier N, Mory O, Garbarg-Chenon A, Téhard B. Incidence of rotavirus gastroenteritis among children under 5 years consulting a paediatrician or a general practitioner in France. Pathol Biol (Paris). 2013 Jun;61(3):99-107. — Pathol Biol (Paris)
Benoit M, Berrut G, Doussaint J, Bakchine S, Bonin-Guillaume S, Frémont P, Gallarda T, Krolak-Salmon P, Marquet T, Mékiès C, Sellal F, Schück S, David R, Robert P. Apathy and Depression in Mild Alzheimer's Disease: A Cross-Sectional Study Using Diagnostic Criteria. J Alzheimers Dis. 2012;31(2):325-34. — J Alzheimers Dis
Tifratene K, Duff FL, Pradier C, Quetel J, Lafay P, Schück S, Benzenine E, Quantin C, Robert P. Use of drug treatments for Alzheimer's disease in France: a study on a national level based on the National Alzheimer's Data Bank (Banque Nationale Alzheimer). Pharmacoepidemiol Drug Saf. 2012 Sep;21(9):1005-12. — Pharmacoepidemiol Drug Saf
Le Duff F, Develay AE, Quetel J, Lafay P, Schück S, Pradier C, Robert P; French National Alzheimer dataBank (BNA). The 2008-2012 French Alzheimer plan: description of the national Alzheimer information system. J Alzheimers Dis. 2012;29(4):891-902. — J Alzheimers Dis
Parez N, Mory O, Pozzetto B, Garbag-Chenon A, Pillet S, Texier N, Téhard B. Impact of Rotavirus gastroenteritis requiring hospitalization or presenting to emergency room among children less than 5 years in France. Pathol Biol (Paris). 2012 Oct;60(5):275-81. — Pathol Biol (Paris)
Le Duff F, Duport N, Gonfrier S, Lafay P, Texier N, Schück S, Pradier C, Robert P. Mise en place du recueil épidémiologique national et premières tendances. Plan national Alzheimer 2008-2012 – Mesure 34. Revue de Gériatrie. — Revue de Gériatrie
Dellamonica P, Katlama C, Cabié A, Texier N, Finkielsztejn L. Durability and Tolerability of Fosamprenavir/Ritonavir Containing Regimens in HIV-Infected Patients with or without Hepatitis B or C Co-Infection: Results from a Large French Cohort in Clinical Practice. AIDS and Clinical Research. — AIDS and Clinical Research
Brodie M, Dupont S, Francia A, Nakken K, Pardo J, Stefan H, Chouette I. Pooled analysis of individual patient data from European observational studies on zonisamide use in clinical practice: Sub-group comparisons of efficacy. 65th annual meeting American Epilepsy Society. Baltimore. Poster. — Epilepsia (Suppl)
Devillier P, Godard P, Pribil C, Decuypere L, Gaudin AF, Martin J, Doussaint J, Nachbaur G, Neukirch F, Van Ganse E, Viens G, Roche N. Control of persistent asthma patients on inhaled corticosteroids in a real-life setting. European Respiratory Society Annual Congress. Barcelona. — Eur Respir J (Suppl)
Dupont S, Verny M, Harston S, Cartz-Piver L, Schück S, Martin J, Puisieux F, Alecu C, Vespignani H, Marchal C, Derambure P. Seizures in the elderly: development and validation of a diagnostic algorithm. Epilepsy Res. 2010 May;89(2-3):339-48. — Epilepsy Res
El Hasnaoui A, Martin J, Salhi H, Doble A. Validation of the Asthma Control Test questionnaire in a North African population. Respir Med. 2009 Dec;103 Suppl 2:S30-7. — Respir Med
Benkheder A, Bouacha H, Nafti S, Taright S, El Ftouh M, Yassine N, Fakhfakh H, Ali-Khoudja M, Texier N, El Hasnaoui A. Control of asthma in the Maghreb: results of the AIRMAG study. Respir Med. 2009 Dec;103 Suppl 2:S12-20. — Respir Med
El Ftouh M, Yassine N, Benkheder A, Bouacha H, Nafti S, Taright S, Fakhfakh H, Ali-Khoudja M, Texier N, El Hasnaoui A. Paediatric asthma in North Africa: the Asthma Insights and Reality in the Maghreb (AIRMAG) study. Respir Med. 2009 Dec;103 Suppl 2:S21-9. — Respir Med
Nafti S, Taright S, El Ftouh M, Yassine N, Benkheder A, Bouacha H, Fakhfakh H, Ali-Khoudja M, Texier N, El Hasnaoui A. Prevalence of asthma in North Africa: the Asthma Insights and Reality in the Maghreb (AIRMAG) study. Respir Med. 2009 Dec;103 Suppl 2:S2-11. — Respir Med
Schück S, Texier N. Biosimilars: The French policy. Int J Risk Saf Med. 2009;21(1-2):41-5. — Int J Risk Saf Med
Schück S, Texier N, Dubois B, Dartigues JF, Touchon J, Rouaud O et al. Description de l'activité des CMRR (Centres mémoire, de ressources et de recherches) et CM (Centres mémoire) utilisant le dossier informatisé Calliope. Cah Annee Gerontol. Vol. 1, pp. 26–33, 2009. DOI: 10.1007/s12612-009-0005-0 — Cah Annee Gerontol
Schück S, Robert PH, Touchon J. Drug benefits and risks; International Textbook of Clinical Pharmacology. IOS Press and Uppsala Monitoring Centre. Amsterdam. Chinese Edition. — Book Chapter - IOS Press
Perrocheau G, Tehard B, Terpereau A, Doussaint J, Campone M. Clinical outcomes and health care resource utilisation of patients receiving lapatinib for breast cancer in France: the LAPS study. ISPOR European Congress. — ISPOR European Congress
Rondeau V, Allain H, Backchine S, Bonet P, Brudon F, Chauplannaz G, Dubois B, Gallarda T, Lepine JP, Pasquier F, Pouchain D, Ritchie K, Robert P, Touchon J, Vellas B, Vercelletto M, Verny M, Carcaillon L, Duveau F, Millet V, Tonelli I, Dartigues J. General practice-based intervention for suspecting and detecting dementia in France: A cluster randomized controlled trial. Dementia. 2008;7:433–50. — Dementia
Allain H, Schück S, Nachit-Ouinekh F, Plouin P, Brunon AM, Boulliat J, Mercier F, Slama A, Baulac M, El Hasnaoui A. Improvement in quality of life after initiation of lamotrigine therapy in patients with epilepsy in a naturalistic treatment setting. Seizure. 2007 Mar;16(2):173-84. — Seizure
Crochard A, El Hasnaoui A, Pouchain D, Huas D, Arnulf I, Krieger J, Lainey E, Le Jeunne P, Leger D, Schuck S, Texier N, Tison F, Montplaisir J. Diagnostic indicators of restless legs syndrome in primary care consultations: the DESYR study. Mov Disord. 2007 Apr 30;22(6):791-7. — Mov Disord
Garrido P, González-Larriba JL, Insa A, et al. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 2007 Oct;25(30):4736-4742. DOI: 10.1200/jco.2007.12.0014. PMID: 17947721. — J Clin Oncol
Díaz-Rubio, Eduardo et al. “Phase III study of capecitabine plus oxaliplatin compared with continuous-infusion fluorouracil plus oxaliplatin as first-line therapy in metastatic colorectal cancer: final report of the Spanish Cooperative Group for the Treatment of Digestive Tumors Trial.” Journal of clinical oncology : official journal of the American Society of Clinical Oncology 25 27 (2007): 4224-30 . — J Clin Oncol
Fourcade RO, Picot MC, Gaudin AF, Texier N, Slama A. Factors determining treatment strategies for patients with benign prostatic hyperplasia. The DUO study. Presse Med. 2007 May;36(5 Pt 1):755-63. — Presse Med
Fourcade RO, Picot MC, Gaudin AF, Texier N, Slama A. Management of patients with benign prostatic hyperplasia by urologists: the DUO study. Ann Urol (Paris). 2006 Nov;40 Suppl 3:S58-63. — Ann Urol (Paris)
Tillie-Leblond I, Masure F; pour le groupe EXACO. 'EXACO': four year follow-up of exacerbations in a cohort of patients with COPD. Rev Mal Respir. 2006 Sep;23(4 Pt 1):377-84. — Rev Mal Respir
Laforest L, Ritleng C, Pribil C, El Hasnaoui A, Schück S, Liesl O, Van Ganse E. Typology of asthma patients who stop using controller therapy: a survey in general practice. European Respiratory Society Annual Congress. Stockholm. — Eur Respir J (Suppl)
Cassinello J, Alvarez JV, López MJ, Pujol E, Colmenarejo A, Segovia F, Marcos F, Filipovich E, Arcediano A, Castro IG. Multicenter phase II study of fixed sequences of capecitabine combined with oxaliplatin or irinotecan in patients with previously untreated metastatic colorectal cancer. Clin Colorectal Cancer. 2006 Mar;5(6):429-35. doi: 10.3816/ccc.2006.n.014. PMID: 16635282. — Clin Colorectal Cancer
Camps C, Massuti B, Jiménez A, et al. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. Annals of Oncology : Official Journal of the European Society for Medical Oncology. 2006 Mar;17(3):467-472. DOI: 10.1093/annonc/mdj115. PMID: 16371411. — Ann Oncol
Pouchain D, Huas D, for the Study Group. A simplified severity scale for the assessment of restless legs syndrome: The DESYR study group. 59th European General Practice Research Workshop. Malta. Poster. — Poster
Touchon J, Dartigues JF, Schück S, Tonelli I. The IMAGINE study. Psychogeriatrics. 2006;6(s1):S8-9. — Psychogeriatrics
Lantéri-Minet M, Allain H, Nachit-Ouinekh F, Bentué-Ferrer D, Gilbert P, Schück S, El Hasnaoui A; Comité d'Orientation National. NOEMIE: an epidemiological study of migraine at work: results from 17 occupational health centres. Rev Neurol (Paris). 2004 Oct;160(10):928-34. — Rev Neurol (Paris)
Robert PH, Schuck S, Dubois B, Olié JP, Lépine JP, Gallarda T, Goni S, Troy S; Investigators' Group. Screening for Alzheimer's disease with the short cognitive evaluation battery. Dement Geriatr Cogn Disord. 2003;15(2):92-8. — Dement Geriatr Cogn Disord
Robert PH, Schuck S, Dubois B, Lépine JP, Gallarda T, Olié JP, Goni S, Troy S. Validation of the Short Cognitive Battery (B2C). Value in screening for Alzheimer's disease and depressive disorders in psychiatric practice. Encephale. 2003 May-Jun;29(3 Pt 1):266-72. — Encephale
